Track topics on Twitter Track topics that are important to you
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.
Amgen buying Onyx which was earlier targeted by Pfizer and Novartis as well.
Medtronic is launching its Resolute Onyx drug-eluting stent in Japan today. -More-
Sunderland-based chemistry expert Onyx Scientific has strengthened its US presence with the appointment of a Chicago-based business development director. Dan Brisard will oversee the contract ma...
Sunderland-based chemistry specialist Onyx Scientific has further strengthened its US team with the appointment of another business development professional. Adam Moorhouse joins the contract res...
Life Sciences Jobs ...
Newcells Biotech and HeartScan appoint marketing comms agency
Will develop a marketing strategy for the UK-based firm
Joseph Leveque has joined Armo BioSciences as chief medical officer. Leveque will oversee the late-stage clinical testing of Armo’s lead cancer immunotherapy candidate, as well as the rest of the Re...
Bacitracin Ointment, USP
Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash
Major Pharmaceuticals Antacid Tablets Drug Facts
EYEWASH STATION ADDITIVE CONCENTRATE
To assess the safety and efficacy of the novel Resolute (R-) Onyx drug-eluting stent (DES).
Transvenous embolization is an effective method for treating dural arteriovenous fistulas (DAVFs) of the transverse-sigmoid sinus (TSS). However, in cases of complicated DAVFs, it is difficult to pres...
Safety of Onyx Transarterial Embolization of Skull Base Dural Arteriovenous Fistulas from Meningeal Branches of the External Carotids also Fed by Meningeal Branches of Internal Carotid or Vertebral Arteries.
To analyze the angiographic and clinical results of transarterial embolization with Onyx (Medtronic-Covidien, Irvine, CA) in dural arteriovenous fistulas (DAVFs) partially fed by arteries arising from...
Microplastics exposure could be detrimental to marine organisms especially under high concentrations. However, few studies have considered the multiphasic nature of marine invertebrates' life history ...
Last year, for the ﬁrst time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the ﬁeld of medicinal chemistry.
The purpose of this study is to evaluate the relative effectiveness and safety of Onyx stent compared to other (drug eluting stents) DES.
The objectives of this study are 1. To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Resolute Onyx™ stent. ...
RATIONALE: A specially modified virus called ONYX-015 may be able to kill tumor cells while leaving normal cells undamaged. Drugs used in chemotherapy use different ways to stop tumor cell...
Test whether AVMs treated with Onyx is equivalent to treatment with n-BCA. Success is defined as an AVM size reduction greater than 50%
To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developi...
Onyx Pharmaceuticals, Inc. is engaged in the discovery and development of novel therapeutics based upon the genetics of human disease, with an emphasis on cancer. The Company's strategy is to capitali...
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3
Onyx Scientific is one of the fastest growing pharmaceutical service companies in the UK. We have more than 40 expert scientists specialising in drug development from medicinal chemistry to early stag...
Onyx Environmental Services is the leading provider of environmental services in the United States. Our network of service centers, treatment, recovery and disposal facilities, sales offices and trans...
We have published hundreds of Onyx Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Onyx Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Onyx Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Onyx Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Onyx Pharmaceuticals, Inc. Drugs and Medications on this site too.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers) - Mouth cancer can develop on the lip, the tongue, the floor...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...